Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Mycosis Fungoides 5Endometrial Neoplasms 5Breast Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Thyroid Neoplasms 3Sezary Syndrome 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Brenner Tumor 3Brain Neoplasms 3

Interventions

Cisplatin 7Gemcitabine 6pembrolizumab 4Radiotherapy, Intensity-Modulated 4toripalimab 2Bevacizumab 2tocilizumab 1tislelizumab 1spartalizumab 1penpulimab 1atezolizumab 1Vitamin D 1Tablets 1Surveys and Questionnaires 1Phantoms, Imaging 1Oral Hygiene 1Observation 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Disulfides 1Dexamethasone 1Chemoradiotherapy 1Cetuximab 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Immunoglobulin G × 1 year × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡